|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Gelatinase A activity directly modulates melanoma cell adhesion and spreading.
|
7534227 |
1995 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, a long-term treatment (7 days) with these drugs markedly down-regulated the genes for both gelatinase A and B. Zymographic analysis showed that human melanoma primarily secretes the gelatinase-A activity, which showed changes similar to those seen in the corresponding mRNA after the treatments with interferons.
|
8056455 |
1994 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
When B16-BL6 melanoma cells or Lewis lung carcinoma cells were implanted intradermally, the tumor volumes at 3 weeks after implantation in the gelatinase A-deficient mice decreased by 39% for B16-BL6 melanoma and by 24% for Lewis lung carcinoma (P < 0.03 for each tumor).The number of lung colonies of i.v. injections fell by 54% for B16-BL6 melanoma and 77% for Lewis lung carcinoma (P < 0.014 and P < 0.0015, respectively).
|
9500469 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since AP-2 also regulates other genes that are involved in the progression of human melanoma such as c-KIT, E-cadherin, MMP-2, and p21(WAF-1), we propose that loss of AP-2 is a crucial event in the development of malignant melanoma.
|
9632718 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For instance, a RAR alpha antagonist suppressed MMP-1 and MMP-2 synthesis in the melanoma cell line, but not in the FaDu or SCC-25 cells.
|
10415749 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that of all tested components of the matrix metalloproteinase system, only expression of activated MMP-2 correlates with increased malignancy in our melanoma xenograft model, corroborating an important role of MMP-2 in human melanoma invasion and metastasis.
|
10555745 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that anterior lens capsule type IV collagen or specifically the synthetic peptide alpha3(IV) 185-203 inhibited both the migration of melanoma or fibrosarcoma cells as well as the activation of membrane-bound MMP-2 by decreasing the expressions of MT1-MMP and the beta3 integrin subunit.
|
10667602 |
2000 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plating cells onto type I or type IV collagen did not trigger pro-MMP-2 activation; on the contrary, conversion of pro-MMP-2 to its active form could be evidenced when melanoma cell lines were seeded in a three dimensional type I collagen lattice.
|
10763911 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This novel mechanism of action of wild-type p53 gene transfer may contribute to its antitumor effect by downregulating cell invasion and matrix metalloproteinase-2 secreted levels in mutated p53 human melanoma cell lines.
|
10844565 |
2000 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In parallel to CD44v3, MMP-2 expression (determined using immunohistochemistry) was significantly elevated (P<0.05) but only in the organ metastatic group of MM.
|
11764382 |
2001 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells.
|
11918086 |
2002 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2.
|
12789289 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Upregulation of MMP-2 activation by ED led to enhanced melanoma cells invasion through S-Gal occupancy.
|
15009703 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also demonstrate that: (1) among the major pro-angiogenic genes, FGF-2 was not increased before or after irradiation and vascular endothelial growth factor strongly inhibited after irradiation; (2) expression of two important metalloproteinases, matrix metalloproteinase 2 and 9, involved in melanoma metastasis were decreased before and after irradiation; (3) expression of their major inhibitor, tissue inhibitor of metalloproteinase, was mainly upregulated; and (4) that invasion of BRCA1 downregulated cells was modified.
|
15009718 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Immunolabeling of melanoma cells with antibodies specific for MMP-2 and MMP-9 led to the identification of two distinct populations of small cytoplasmatic vesicles containing MMP-2 or MMP-9, respectively.
|
15604254 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Because MMP-2 activity is critical for melanoma progression, the MMP-2 peptide should be cross-presented by most progressing melanomas and represents a unique antigen for vaccine therapy of these tumors.
|
15998788 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because MMP-2 activity is critical for melanoma progression, the MMP-2 peptide should be cross-presented by most progressing melanomas and represents a unique antigen for vaccine therapy of these tumors.
|
15998788 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma.
|
16047212 |
2005 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis.
|
16306050 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment.
|
16379022 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data indicate that activation of Jak/Vav/Rho GTPase pathway by CXCL12 is a key signaling event for MT1-MMP/MMP-2-dependent melanoma cell invasion.
|
16397238 |
2006 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, M21/OPN cells exhibit increased motility, which is markedly reduced upon treatment with inhibitors to alpha(v) and MMP-2.
|
16631740 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Most melanoma cell lines and cultured normal melanocytes produced high levels of matrix metalloproteinase-2.
|
16718267 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The myriad of biological effects exerted by elastokines on stromal and inflammatory cells led us to hypothesize that they might be main actors in elaborating a favorable cancerization field in melanoma; for instance these peptides could catalyze the vertical growth phase transition in melanoma through increased expression of gelatinase A and membrane-type 1 matrix metalloproteinase.
|
17498549 |
2007 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
30%) attenuated the invasive activity of melanoma cells in a cell-based invasion assay and reduced MMP2 activity in the supernatant of melanoma cells.
|
17845054 |
2007 |